Rupture of totally implantable central venous access devices (Intraports) in patients with cancer: Report of four cases

被引：26
作者：
Filippou D.K. [1 ,2 ]
Tsikkinis C. [1 ,3 ]
Filippou G.K. [2 ]
Nissiotis A. [1 ,2 ]
Rizos S. [1 ,2 ]
机构：
[1] Department of Surgical Oncology, A.A. Kifissias Anticancer Hospital, Kifissias
[2] 1st Surgical Department, GPHP Tzanion Hospital, Piraeus, Athens
[3] 3rd Surgical Department, Piraeus Anticancer Hospital Metaxa, Piraeus
来源：
World Journal of Surgical Oncology | / 2卷 / 1期
关键词：
Catheter; Enoxaparin; Subclavian Vein; Catheter Removal; Fluoroscopic Control;
D O I：
10.1186/1477-7819-2-36
中图分类号：
学科分类号：
摘要：
Background: Totally implantable central venous access devices (intraports) are commonly used in cancer patients to administer chemotherapy or parenteral nutrition. Rupture of intraport is a rare complication. Patients and methods: During 3 years period, a total of 245 intraports were placed in cancer patients for chemotherapy. Four of these cases (two colon cancer and one each of pancreas and breast cancer) had rupture of the intraport catheter, these forms the basis of present report. Results: Mean time insitu for intraports was 164∀35 days. Median follow-up time was 290 days and total port time in situ was 40180 days. The incidence of port rupture was 1 per 10,000 port days. Three of the 4 cases were managed by successful removal of catheters. In two of these the catheter was removed under fluoroscopic control using femoral route, while in the third patient the catheter (partial rupture) was removed surgically. One of the catheters could not be removed and migrated to right ventricle on manipulations. Conclusion: Port catheter rupture is a rare but dreaded complication associated with subcutaneous port catheter device placement for chemotherapy. In case of such an event the patient should be managed by an experienced vascular surgeon and interventional radiologist, as in most cases the ruptured catheter can be retrieved by non operative interventional measures. © 2004 Filippou et al; licensee BioMed Central Ltd.
引用
收藏
页数：5
相关论文
共 14 条
  • [1] Biffi R., Corrado F., de Braud F., de Lucia F., Scarpa D., Testori A., Orsi F., Bellomi M., Mauri S., Aapro M., Andreoni B., Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumors. Experience of 178 cases using a single type of device, Eur. J. Cancer, 33, pp. 1190-1194, (1997)
  • [2] Kurul S., Saip P., Aydin T., Totally implantable venous-access ports: Local problems and extravasation injury, Lancet Oncol., 3, pp. 684-692, (2002)
  • [3] Talfer S., Conessa C., Herve S., Rogouet E., de Rotalier P., Poncet J.L., Complications with totally implantable venous access device. A retrospective of 116 cases, Presse Med., 32, pp. 1263-1268, (2003)
  • [4] Aubaniac R., L' injection intraveineuse sous-claviculaire: Avantages et technique, Presse Med., 60, pp. 1456-1458, (1952)
  • [5] Yedlicka Jr. J.W., Carlson J.E., Hunter D.W., Castaneda-Zuniga W.R., Amplatz K., Nitinol goose-neck snare for removal of foreign bodies. Experimental study and clinical evaluation, Radiology, 178, pp. 691-693, (1991)
  • [6] Vasquez R.M., Brodski E.G., Primary and secondary malposition of silicon central venous catheters, Acta Anaesthesiol. Scand., 81, pp. 22-25, (1985)
  • [7] Koulas S., Karahalios N., Kotzias N., Filippou D., Efthimiadou S., Nissiotis A., Infectious and other complications in totally implantable venous access port catheters, (1997)
  • [8] Brothers T.E., Von Moll L.K., Niederhuber J.E., Roberts J.A., Walker-Andrews S., Ensminger W.D., Experience with subcutaneous infusion ports in three hundred patients, Surg. Gynecol. Obstet., 166, pp. 295-301, (1988)
  • [9] Marie O., Leverger G., Douard M.C., Mourey F., Roche A., Eurin B., Migration intravsculaire de fragments de catheters veineux centraux, Presse Med., 15, pp. 1270-1272, (1986)
  • [10] Ballarini C., Intra M., Pisani Ceretti A., Cordovana A., Pagani M., Farina G., Perrone S., Tomirotti M., Scanni A., Spina G.P., Complications of subcutaneous infusion port in the general oncology population, Oncology, 56, pp. 97-102, (1999)
12